Bevacizumab as part of standard first line treatment of ovarian cancer
10 Nov 2010
Bevacizumab as part of standard first line treatment of ovarian cancer
Optimal treatment for colorectal cancer patients with liver metastases
OECI Accreditation
The treatment of advanced pancreatic neuroendocrine tumours (pNET)
The role of The Christie NHS Foundation Trust within OECI
Eastern Europe breast cancer screening programme
Clinical trial design, biomarkers development and the treatment of neuropathic pain
Investigating mTOR as a treatment for neuroendocrine tumours
Cabergoline treatment of acromegaly
A new pharmacological target for somatotroph pituitary adenomas
The treatment of pituitary tumours
Aggressive pituitary tumours